QTXB SEC-arkiveringar - QuantRx Biomedical Corporation- Årsredovisning, Fullmaktsutlåtande, prospekt

Grundläggande statistik

CIK

820608

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to QuantRx Biomedical Corporation

SEC Filings (Chronological Order)

Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.

November 14, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO
August 24, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 22, 2022 Commission File Number 000-17119 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter.
August 22, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPORATIO
August 16, 2022	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
May 16, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPORATI
April 15, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CORPOR
March 31, 2022	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING NT 10-K 1 form12b25-03312022110356.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-17119 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ x ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-
November 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO
November 15, 2021	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
August 16, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPORATIO
May 17, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTR
April 15, 2021	10-K	Annual Report - ANNUAL REPORT 10-K 1 qtxb10kdec312020.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi
April 1, 2021	NT 10-K	- OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
November 17, 2020	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
November 17, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C
August 14, 2020	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR
May 20, 2020	10-Q	Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO
May 15, 2020	NT 10-Q	- OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
April 14, 2020	10-K	QTXB / QuantRX Biomedical Corp. 10-K - Annual Report - ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO
March 30, 2020	NT 10-K	QTXB / QuantRX Biomedical Corp. NT 10-K - - OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
November 19, 2019	10-Q	QTXB / QuantRX Biomedical Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C
November 14, 2019	NT 10-Q	QTXB / QuantRX Biomedical Corp. NT 10-Q - - NT 10-Q 1 form12b25-11142019011105.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-17119 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N-
August 15, 2019	10-Q	QTXB / QuantRX Biomedical Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR
August 14, 2019	NT 10-Q	QTXB / QuantRX Biomedical Corp. NT 10-Q - - OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
May 20, 2019	10-Q	QTXB / QuantRX Biomedical Corp. 10-Q - Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO
May 15, 2019	NT 10-Q	QTXB / QuantRX Biomedical Corp. NT 10-Q NT 10-Q 1 form12b25-05152019080512.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-17119 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N-
April 16, 2019	10-K	QTXB / QuantRX Biomedical Corp. ANNUAL REPORT (Annual Report) 10-K 1 qtxb10kdec312018.htm ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi
April 1, 2019	NT 10-K	QTXB / QuantRX Biomedical Corp. OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
November 19, 2018	EX-10.1	Amendment No. 1 to the Asset Purchase Agreement, by and between QuantRx Biomedical Corporation and Preprogen LLC, dated October 8, 2018 (incorporated by reference to Exhibit 10.1 filed with Form 10-Q on November 19, 2018). EXHIBIT 10.1 AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT This AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT (this “Amendment”), dated October 8, 2018, is made by and between QuantRx Biomedical Corporation, a Nevada corporation (“Seller”), and Preprogen LLC, a Delaware limited liability company (“Buyer”). Buyer and Seller are collectively referred to herein as the “Parties” and each individually as a
November 19, 2018	10-Q	QTXB / QuantRX Biomedical Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C
November 14, 2018	NT 10-Q	QTXB / QuantRX Biomedical Corp. NT 10-Q NT 10-Q 1 form12b25-11142018101150.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-17119 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N-
August 20, 2018	10-Q	QTXB / QuantRX Biomedical Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR
August 14, 2018	NT 10-Q	QTXB / QuantRX Biomedical Corp. NT 10-Q NT 10-Q 1 form12b25-08142018120821.htm OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response ... 2.50 SEC FILE NUMBER 000-17119 CUSIP NUMBER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [ x ] Form 10-Q [ ] Form 10-D [ ] Form N-
May 21, 2018	10-Q	QTXB / QuantRX Biomedical Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO
May 15, 2018	NT 10-Q	QTXB / QuantRX Biomedical Corp. NT 10-Q OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
April 17, 2018	10-K	QTXB / QuantRX Biomedical Corp. ANNUAL REPORT (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO
March 30, 2018	NT 10-K	QTXB / QuantRX Biomedical Corp. NT 10-K OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
December 21, 2017	EX-10.6	Warrant to Purchase 15,000,000 Shares of Common Stock of QuantRx, dated December 14, 2017 (incorporated by reference to Exhibit 10.6 filed with Form 8-K on December 21, 2017). EX-10.6 7 ex10-6.htm WARRANT, DATED DECEMBER 14, 2017 Exhibit 10.6 THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. SUCH SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT AND ANY APPLICABLE STAT
December 21, 2017	EX-10.4	Intellectual Property License Agreement, dated December 14, 2017, by and between QuantRx Biomedical Corporation and Preprogen LLC (incorporated by reference to Exhibit 10.4 filed with Form 8-K on December 21, 2017). Exhibit 10.4 Exhibit 10.4 INTELLECTUAL PROPERTY LICENSE AGREEMENT This Intellectual Property License Agreement (?Agreement?) is entered into as of December 14, 2017 (the ?Effective Date?), by and between QuantRX Biomedical Corporation, a Nevada Corporation (?Licensee?), and Preprogen LLC, a Delaware corporation (?Licensor?). RECITALS: WHEREAS, Licensor and Licensee are parties to that certain Asse
December 21, 2017	EX-10.1	Asset Purchase Agreement, dated December 14, 2017, by and between QuantRx Biomedical Corporation and Preprogen LLC (incorporated by reference to Exhibit 10.1 filed with Form 8-K on December 21, 2017). Exhibit 10.1 Exhibit 10.1 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (this ?Agreement?), dated December 14, 2017, is made by and between QuantRx Biomedical Corporation, a Nevada corporation (?Seller?), and Preprogen LLC, a Delaware limited liability company (?Buyer?). Buyer and Seller are collectively referred to herein as the ?Parties? and each individually as a ?Party?. WHEREAS, the
December 21, 2017	EX-10.5	Escrow Agreement, dated December 14, 2017 (incorporated by reference to Exhibit 10.5 filed with Form 8-K on December 21, 2017). Exhibit 10.5 Exhibit 10.5 ESCROW AGREEMENT (Basic Three Party Escrow) THIS ESCROW AGREEMENT is entered into as of December 14, 2017, by and among Preprogen LLC, a Delaware limited liability company (?Party A?), QuantRx Biomedical Corporation, a Nevada corporation (?Party B?, and together with Party A, sometimes referred to individually as ?Party? and collectively as the ?Parties?), and JPMorgan Ch
December 21, 2017	EX-10.3	Trademark Assignment Agreement, dated December 14, 2017, by and between QuantRx Biomedical Corporation and Preprogen LLC (incorporated by reference to Exhibit 10.3 filed with Form 8-K on December 21, 2017). EX-10.3 4 ex10-3.htm TRADEMARK ASSIGNMENT, DATED DECEMBER 14, 2017 Exhibit 10.3 TRADEMARK ASSIGNMENT AGREEMENT This TRADEMARK ASSIGNMENT AGREEMENT (this “Trademark Assignment Agreement”) is made as of December 14, 2017 by and between QuantRx Biomedical Corporation, a Nevada corporation (“Assignor”), and Preprogen LLC, a Delaware limited liability company (“Assignee”). WHEREAS, Assignor and Assigne
December 21, 2017	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 qtxb8kdec152017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2017 QUANTRX BIOMEDICAL CORPORATION (Exact name of Registrant as specified in its Charter) Nevada 000-17119 33-0202574 (State or ot
December 21, 2017	EX-10.2	Patent Assignment Agreement, dated December 14, 2017, by and between QuantRx Biomedical Corporation and Preprogen LLC (incorporated by reference to Exhibit 10.2 filed with Form 8-K on December 21, 2017). Exhibit 10.2 Exhibit 10.2 PATENT ASSIGNMENT AGREEMENT This PATENT ASSIGNMENT AGREEMENT (?Agreement?) is made as of December 14, 2017, by and between QuantRx Biomedical Corporation, a Nevada corporation (?Assignor?), and Preprogen LLC, a Delaware limited liability company (?Assignee?). WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement, dated as of December 14, 2017
November 20, 2017	10-Q	QTXB / QuantRX Biomedical Corp. QUARTERLY REPORT (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C
November 20, 2017	EX-10.1	NOTE PURCHASE AGREEMENT EX-10.1 2 ex10-1.htm FORM OF CONVERTIBLE PROMISSORY DEMAND NOTE. Exhibit 10.1 NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”) is made as of July 1, 2017 and between QuantRx Biomedical Corp. (the “Company”), a Nevada corporation, with offices at 10190 SW 90th Avenue, Tualatin, OR 97123 and the purchaser identified on the signature page hereto (the “Purchaser”). WHEREAS, the
November 14, 2017	NT 10-Q	QTXB / QuantRX Biomedical Corp. 0-Q QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
October 5, 2017	10-K/A	QTXB / QuantRX Biomedical Corp. AMENDMENT NO. 1 TO FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 Q
October 5, 2017	CORRESP	QTXB / QuantRX Biomedical Corp. ESP QuantRx Biomedical Corporation - FORM correspondence October 5, 2017 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
August 21, 2017	EX-10.1	Form of Convertible Demand Purchase Note, dated July 1, 2017 (incorporated by reference to Exhibit 10.1 filed with Form 10-Q on August 20, 2017). Exhibit 10.1 THIS NOTE AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR UNLESS THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSE
August 21, 2017	10-Q	QTXB / QuantRX Biomedical Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR
August 14, 2017	NT 10-Q	QuantRX Biomedical 0-Q QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
May 22, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO
May 15, 2017	NT 10-Q	QuantRX Biomedical 0-Q OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
April 17, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 [ ] TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO
March 29, 2017	NT 10-K	QuantRX Biomedical 0-K QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
December 2, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C
November 14, 2016	NT 10-Q	QuantRX Biomedical 0-Q QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
August 17, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR
August 15, 2016	NT 10-Q	QuantRX Biomedical 0-Q QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
August 15, 2016	NT 10-Q	QuantRX Biomedical 0-Q QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
May 20, 2016	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO
May 16, 2016	NT 10-Q	QuantRX Biomedical 0-Q QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
April 13, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 [ ] TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO
March 30, 2016	NT 10-K	QuantRX Biomedical 0-K QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: October 31, 2018 Estimated average burden hours per response .
November 16, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C
August 17, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR
August 13, 2015	NT 10-Q	QuantRX Biomedical 0-Q QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
July 22, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO
July 22, 2015	EX-10.1	Convertible Promissory Demand Note Exhibit 10.1 THIS NOTE AND THE SECURITIES INTO WHICH IT IS CONVERTIBLE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR UNLESS THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSE
May 15, 2015	NT 10-Q	QuantRX Biomedical 0-Q QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
April 15, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 [ ] TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO
March 31, 2015	NT 10-K	QuantRX Biomedical THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. QuantRx Biomedical Corporation - FORM form12b-25 OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
March 26, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers QuantRx Biomedical Corporation - FORM 8-k UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 21, 2015 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No.
March 4, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2015 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No.
March 4, 2015	EX-99.1	QuantRx® Biomedical Provides Update on Technological Progress of its Genomic Diagnostics Platforms Well Positioned in the Emerging Field of Fetal Genomics Exhibit 99.1 For Immediate Release QuantRx® Biomedical Provides Update on Technological Progress of its Genomic Diagnostics Platforms Well Positioned in the Emerging Field of Fetal Genomics TUALATIN, OR – March 3, 2015 – QuantRx® Biomedical Corporation (“QuantRx” or the “Company”) (OTCBB:QTXB), an emerging provider of innovative healthcare solutions for feminine care, laboratory based point-of-car
February 25, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2015 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No.
February 25, 2015	EX-99.1	QuantRx® Biomedical Provides Update on Corporate Developments Exhibit 99.1 QuantRx® Biomedical Provides Update on Corporate Developments TUALATIN, OR-(Marketwired - Feb 25, 2015) - QuantRx® Biomedical Corporation ("QuantRx" or the "Company") (OTCQB: QTXB), an emerging provider of innovative healthcare solutions for feminine care, point-of-care diagnostics, laboratory diagnostics and genomic testing, all of which leverage its robust portfolio of patented inte
November 18, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL C
November 14, 2014	NT 10-Q	QTXB / QuantRX Biomedical Corp. NT 10-Q - - THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
August 19, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPOR
August 14, 2014	NT 10-Q	QTXB / QuantRX Biomedical Corp. NT 10-Q - - THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
May 23, 2014	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A (Amendment No. 1) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUA
May 20, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 000-17119 QUANTRX BIOMEDICAL CORPO
May 15, 2014	NT 10-Q	- THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
May 6, 2014	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 [ ] TRANSITION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 Q
April 30, 2014	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 [ ] TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL
April 14, 2014	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 [ ] TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO
April 14, 2014	EX-3.6	Certificate of Withdrawal of the Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock, dated November 19, 2010 (incorporated by reference to Exhibit 3.6 filed with Form 10-K on April 14, 2014). Exhibit 3.6
April 14, 2014	EX-3.5	Certificate of Amendment to the Articles of Incorporation dated January 25, 2010 (incorporated by reference to Exhibit 3.5 filed with Form 10-K on April 14, 2014). Exhibit 3.5
March 31, 2014	NT 10-K	- THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
November 19, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORP
November 14, 2013	NT 10-Q	- THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
August 14, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATI
May 20, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORAT
May 14, 2013	NT 10-Q/A	- THIS IS A NT 10-Q/A ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
May 14, 2013	NT 10-K	- THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
April 15, 2013	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 [ ] TRANSITION REPORT PURSUANT TO S UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CO
April 1, 2013	NT 10-K	- THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: August 31, 2015 Estimated average burden hours per response .
November 16, 2012	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 o TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANT
November 14, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 OR [ ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORP
October 26, 2012	CORRESP	- QuantRx Biomedical Corporation 10190 SW90th Avenue, No. 4690, Tualatin, Oregon 97123 October 26, 2012 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 4561 Washington, D.C. 20549 Attention: Kevin L. Vaughn, Accounting Branch Chief RE: QuantRx Biomedical Corporation Form 10-K for the fiscal year ended December 31, 2011 Filed Ap
October 2, 2012	CORRESP	- QuantRx Biomedical Corporation P.O. Box 4960, Portland, Oregon 97062 October 2, 2012 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 4561 Washington, D.C. 20549 Attention: Kevin L. Vaughn, Accounting Branch Chief RE: QuantRx Biomedical Corporation Form 10-K for the fiscal year ended December 31, 2011 Filed April 17, 2012 File
August 21, 2012	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPOR
August 20, 2012	10-Q	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORAT
August 14, 2012	NT 10-Q	- THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: July 31, 2012 Estimated average burden hours per response .
May 21, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION
May 15, 2012	NT 10-Q	- THIS IS A NT 10-Q ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response .
April 17, 2012	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 o TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CORPOR
March 27, 2012	NT 10-K	- THIS IS A NT 10-K ATTACHMENT FILE IN HTM FORMAT. OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response .
March 1, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 1, 2012 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No.
February 17, 2012	SC 13G	QTXB / QuantRX Biomedical Corp. / BALK MATTHEW Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 QuantRx Biomedical Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 74765N109 (CUSIP Number) December 31 , 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
February 15, 2012	SC 13G	QTXB / QuantRX Biomedical Corp. / ADELMAN JASON T Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 QuantRx Biomedical Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 74765N109 (CUSIP Number) December 31 , 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua
January 17, 2012	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A (Amendment No. 2) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 o TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A (Amendment No. 2) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUAN
January 9, 2012	CORRESP	- QuantRx Biomedical Corporation P.O. Box 4960, Portland, Oregon 97062 January 9, 2012 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 4561 Washington, D.C. 20549 Attention: Martin James, Senior Assistant Chief Accountant RE: QuantRx Biomedical Corporation Form 10-K for the fiscal year ended December 31, 2010 Filed April 14, 20
December 2, 2011	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 o TRANSITION REP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K /A (Amendment No. 1) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUAN
December 2, 2011	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q /A (Amendment No. 1) x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BI
November 18, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORA
November 14, 2011	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response .
November 7, 2011	8-K	Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 1, 2011 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No.
October 28, 2011	CORRESP	- QuantRx Biomedical Corporation P.O. Box 4960, Portland, Oregon 97062 October 28, 2011 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 4561 Washington, D.C. 20549 Attention: Martin James, Senior Assistant Chief Accountant RE: QuantRx Biomedical Corporation Form 10-K for the fiscal year ended December 31, 2010 Filed April 14, 2
October 7, 2011	CORRESP	- QuantRx Biomedical Corporation P.O. Box 4960, Portland, Oregon 97062 October 7, 2011 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E., Mail Stop 4561 Washington, D.C. 20549 Attention: Martin James, Senior Assistant Chief Accountant RE: Quantrx Biomedical Corporation Form 10-K for the fiscal year ended December 31, 2010 Filed April 14, 20
August 16, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION
August 15, 2011	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response .
July 14, 2011	EX-99	QuantRx Biomedical Corporation Provides Corporate Update Exhibit 99.1 QuantRx Biomedical Corporation Provides Corporate Update PORTLAND, Ore., July 14, 2011 /PRNewswire/ - QuantRx® Biomedical Corporation (OTCQB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms, is pleased to announce that following the successful resolution and full settlement of all matters re
July 14, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14 , 2011 Commission File Numb UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14 , 2011 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No.
July 8, 2011	EX-99	SETTLEMENT AGREEMENT AND RELEASE SETTLEMENT AGREEMENT AND RELEASE This Settlement Agreement and Release ("Agreement") is entered into by and between NuRx Pharmaceuticals, Inc.
July 8, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7 , 2011 Commission File Numbe UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 7 , 2011 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No.
May 20, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION
May 13, 2011	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response .
April 14, 2011	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 o TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CORPOR
April 14, 2011	EX-3.6	Certificate of Designation for Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.6 filed with Form 10-K on April 14, 2011). Exhibit 3.6 CERTIFICATE OF DESIGNATION OF THE RELATIVE RIGHTS AND PREFERENCES OF THE SERIES B CONVERTIBLE PREFERRED STOCK OF QUANTRX BIOMEDICAL CORPORATION The undersigned, the Chief Executive Officer of QuantRx Biomedical Corporation, a Nevada corporation (the “Company”), in accordance with the provisions of Section 78.195 of the Nevada Revised Statutes, does hereby certify that, pursuant to the
March 30, 2011	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: May 31, 2012 Estimated average burden hours per response .
January 3, 2011	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 31 , 2010 Commission File Number: 000-17119 QuantRx Biomedical Corporation (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 330202574 (IRS Employer Identification No.
November 19, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORA
November 15, 2010	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-17119 (Check One): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2009 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report
September 1, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2010 QUANTRX BIOMEDI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commi
September 1, 2010	EX-99.1	QuantRx Biomedical Consolidates Operations to Oregon For Immediate Release QuantRx Biomedical Consolidates Operations to Oregon DOYLESTOWN, PA – September 1, 2010 – QuantRx® Biomedical Corporation (OTCBB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide point-of-care healthcare industry, today announced that it will be consolidating its operations in order to better serve its growing market demands.
August 9, 2010	424B3	PROSPECTUS SUPPLEMENT NO. 21 Prospectus Supplement No. 21 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 21 Prospectus Supplement No. 21 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
August 6, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION
July 22, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2010 QUANTRX BIOMEDICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commissio
July 22, 2010	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2010 QUANTRX BIOMEDICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commissio
June 9, 2010	EX-99.1	QuantRx Biomedical Submitted a 510(k) Application to FDA for Thyroid Point-of-Care Testing System Following Successful Completion of Studies Showing Quantitative Results For Immediate Release QuantRx Biomedical Submitted a 510(k) Application to FDA for Thyroid Point-of-Care Testing System Following Successful Completion of Studies Showing Quantitative Results DOYLESTOWN, PA – June 9, 2010 – QuantRx® Biomedical Corporation (OTCBB: QTXB), a broad-based diagnostic company focused on the development and commercialization of innovative diagnostic products, today announced that it has completed clinical testing of the Q-Reader™ thyroid testing system.
June 9, 2010	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commission
May 17, 2010	424B3	PROSPECTUS SUPPLEMENT NO. 20 Prospectus Supplement No. 20 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 20 Prospectus Supplement No. 20 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
May 14, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION
May 6, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2010 QUANTRX BIOMEDICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commissi
May 6, 2010	EX-99.1	QuantRx Biomedical Announces Board of Directors Updates Company Mourns Passing of Board Member Arthur Hull Hays, Jr; Appoints Two New Independent Directors For Immediate Release QuantRx Biomedical Announces Board of Directors Updates Company Mourns Passing of Board Member Arthur Hull Hays, Jr; Appoints Two New Independent Directors DOYLESTOWN, PA – May 6, 2010 – QuantRx® Biomedical Corporation (OTCBB:QTXB), an emerging leader in the development and commercialization of innovative diagnostic products based on its patented technology platforms for the worldwide point-of-care healthcare industry, today announced the appointment of two new independent directors to its Board of Directors; one of the appointments is a replacement for the seat vacated by Arthur Hull Hayes, Jr.
April 7, 2010	424B3	PROSPECTUS SUPPLEMENT NO. 19 Prospectus Supplement No. 19 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 19 Prospectus Supplement No. 19 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
March 31, 2010	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 o TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CORPOR
March 31, 2010	EX-99.1	QN DIAGNOSTICS, LLC FINANCIAL STATEMENTS Table of Contents QN DIAGNOSTICS, LLC FINANCIAL STATEMENTS Table of Contents Report of Independent Registered Public Accounting Firm 2 Balance Sheet as of December 31, 2009 3 Statement of Operations for the Period from July 30, 2009 (inception) to December 31, 2009 4 Statement of Cash Flows for the Period from July 30, 2009 (inception) to December 31, 2009 5 Statement of Members’ Equity for the Period from July 30,
March 31, 2010	EX-99.2	FLUOROPHARMA, INC. (a development stage company) FINANCIAL STATEMENTS Table of Contents FLUOROPHARMA, INC. (a development stage company) FINANCIAL STATEMENTS Table of Contents Report of Independent Registered Public Accounting Firm 2 Balance Sheets 3 Statements of Operations 4 Statements of Cash Flows 5 Statements of Stockholders’ Equity 6 Notes to Financial Statements 7 1 To the Board of Directors and Shareholders FluoroPharma, Inc. REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
March 23, 2010	SC 13D/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) (Amendment No. 1)* SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) Information to be Included in Statements Filed Pursuant to Rule 13d-1(a) and Amendments Thereto Filed Pursuant to Rule 13d-2(a) (Amendment No. 1)* QuantRx Biomedical Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 74765N109 (CUSIP Number) Sherbrooke Partners,
February 9, 2010	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* QuantRx Biomedical Corporation (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 74765N109 (CUSIP Number) December 31, 2009 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul
February 4, 2010	424B3	PROSPECTUS SUPPLEMENT NO. 18 Prospectus Supplement No. 18 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 18 Prospectus Supplement No. 18 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
January 29, 2010	EX-99.2	QuantRx Biomedical to Acquire NuRx Pharmaceuticals Combination Strengthens Financial and Competitive Position QuantRx Biomedical to Acquire NuRx Pharmaceuticals Combination Strengthens Financial and Competitive Position DOYLESTOWN, PA ? January 29, 2010 ? QuantRx Biomedical Corporation (OTCBB: QTXB) today announced that it has entered into an agreement to acquire NuRx Pharmaceuticals, Inc.
January 29, 2010	EX-99.1	VOTING AGREEMENT VOTING AGREEMENT THIS STOCKHOLDER VOTING AGREEMENT (this “Agreement”) is made and entered into as of January , 2010, by and among QuantRx Biomedical Corp.
January 29, 2010	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2010 QUANTRX BIOMEDIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commis
January 29, 2010	EX-2.1	AGREEMENT AND PLAN OF MERGER DATED AS OF JANUARY 29, 2010 BY AND AMONG QUANTRX BIOMEDICAL CORPORATION, NP ACQUISITION CORPORATION NURX PHARMACEUTICALS, INC., TABLE OF CONTENTS EXECUTION COPY AGREEMENT AND PLAN OF MERGER DATED AS OF JANUARY 29, 2010 BY AND AMONG QUANTRX BIOMEDICAL CORPORATION, NP ACQUISITION CORPORATION AND NURX PHARMACEUTICALS, INC.
January 29, 2010	EX-99.1	VOTING AGREEMENT VOTING AGREEMENT THIS STOCKHOLDER VOTING AGREEMENT (this “Agreement”) is made and entered into as of January , 2010, by and among QuantRx Biomedical Corp.
January 29, 2010	EX-99.2	QuantRx Biomedical to Acquire NuRx Pharmaceuticals Combination Strengthens Financial and Competitive Position QuantRx Biomedical to Acquire NuRx Pharmaceuticals Combination Strengthens Financial and Competitive Position DOYLESTOWN, PA – January 29, 2010 — QuantRx Biomedical Corporation (OTCBB: QTXB) today announced that it has entered into an agreement to acquire NuRx Pharmaceuticals, Inc.
January 29, 2010	EX-2.1	AGREEMENT AND PLAN OF MERGER DATED AS OF JANUARY 29, 2010 BY AND AMONG QUANTRX BIOMEDICAL CORPORATION, NP ACQUISITION CORPORATION NURX PHARMACEUTICALS, INC., TABLE OF CONTENTS EXECUTION COPY AGREEMENT AND PLAN OF MERGER DATED AS OF JANUARY 29, 2010 BY AND AMONG QUANTRX BIOMEDICAL CORPORATION, NP ACQUISITION CORPORATION AND NURX PHARMACEUTICALS, INC.
January 29, 2010	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2010 QUANTRX BIOMEDICAL CORPORATION (Exact name of registrant as specified in its charter) Nevada 0-17119 33-0202574 (State or other jurisdiction of incorporation) (Commis
November 20, 2009	424B3	PROSPECTUS SUPPLEMENT NO. 17 Prospectus Supplement No. 17 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 17 Prospectus Supplement No. 17 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
November 16, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORA
November 5, 2009	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary proxy statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive proxy state
October 26, 2009	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: x Preliminary proxy statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive proxy state
August 17, 2009	424B3	PROSPECTUS SUPPLEMENT NO. 16 Prospectus Supplement No. 16 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 16 Prospectus Supplement No. 16 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
August 14, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION
August 14, 2009	8-K/A	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2009 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
August 5, 2009	EX-10.1	EX-10.1
August 5, 2009	EX-3.1	EX-3.1
August 5, 2009	EX-2.1	EX-2.1
August 5, 2009	EX-10.7	EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of , 2009, by and between QuantRx Biomedical Corporation, a Nevada corporation (the “Company”), and Sasha Afanassiev (the “Executive”).
August 5, 2009	EX-10.2	EX-10.2
August 5, 2009	EX-10.8	Employment Agreement, dated July 30, 2009, by and between QuantRx and William Fleming (incorporated by reference to Exhibit 10.8 filed with Form 8-K on August 5, 2009). EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of , 2009, by and between QuantRx Biomedical Corporation, a Nevada corporation (the “Company”), and William Fleming (the “Executive”).
August 5, 2009	EX-10.6	EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?), dated as of , 2009, by and between QuantRx Biomedical Corporation, a Nevada corporation (the ?Company?), and Walter Witoshkin (the ?Executive?).
August 5, 2009	EX-10.5	Warrant to Purchase 2,000,000 Shares of Common Stock of QuantRx, dated July 30, 2009, issued by QuantRx in favor of NuRx (incorporated by reference to Exhibit 10.5 filed with Form 8-K on August 5, 2009).
August 5, 2009	EX-10.4	Warrant to Purchase 2,000,000 Shares of Common Stock of QuantRx, dated July 30, 2009, issued by QuantRx in favor of NuRx (incorporated by reference to Exhibit 10.4 filed with Form 8-K on August 5, 2009).
August 5, 2009	EX-10.3	EX-10.3
August 5, 2009	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 30, 2009 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
May 21, 2009	424B3	PROSPECTUS SUPPLEMENT NO. 15 Prospectus Supplement No. 15 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 15 Prospectus Supplement No. 15 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
May 15, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION
May 11, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2009 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
April 16, 2009	424B3	PROSPECTUS SUPPLEMENT NO. 14 Prospectus Supplement No. 14 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 14 Prospectus Supplement No. 14 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
April 15, 2009	EX-21.1	Subsidiaries of QuantRx Biomedical Corporation As of December 31, 2008 Organized Under Laws of: Percentage of Voting Power FluoroPharma, Inc. Delaware 57.78 % EX-21.1 LIST OF SUBSIDIARIES Subsidiaries of QuantRx Biomedical Corporation As of December 31, 2008 Organized Under Laws of: Percentage of Voting Power FluoroPharma, Inc. Delaware 57.78 %
April 15, 2009	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 o TRANSITION REPORT PURSUANT TO SECTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-17119 QUANTRX BIOMEDICAL CORPOR
February 13, 2009	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* QuantRx Biomedical Corporation (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class Filed by Bowne Pure Compliance OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response.
December 19, 2008	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.
December 18, 2008	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q [X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17
December 18, 2008	10KSB/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB/A Amendment No. 1 to Form 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB/A Amendment No. 1 to Form 10-KSB x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-17119
December 18, 2008	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 to Form 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119
December 18, 2008	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 24, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
December 18, 2008	CORRESP	December 18, 2008 QuantRx Biomedical Corporation 267-880-1595 267-880-1596 [email protected] December 18, 2008 VIA EDGAR TRANSMISSION AND OVERNIGHT DELIVERY Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Lynn Dicker Re: QuantRx Biomedical Corporation Form 10-KSB for year ended December 31, 2007 Filed March 31, 2008 Form 10-Q for the
December 9, 2008	CORRESP	December 9, 2008 Michael D. Helsel 212-801-6962 212-805-9284 [email protected] December 9, 2008 VIA EDGAR TRANSMISSION AND OVERNIGHT DELIVERY Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Lynn Dicker Re: QuantRx Biomedical Corporation Form 10-KSB for year ended December 31, 2007 Filed March 31, 2008 Form 10-Q for the period ended June 30
November 17, 2008	424B3	PROSPECTUS SUPPLEMENT NO. 13 Prospectus Supplement No. 13 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 13 Prospectus Supplement No. 13 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
November 14, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORA
August 29, 2008	424B3	PROSPECTUS SUPPLEMENT NO. 12 Prospectus Supplement No. 12 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 12 Prospectus Supplement No. 12 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
August 27, 2008	EX-4.1	QuantRx Biomedical Corporation Promissory Bridge Note THIS BRIDGE NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
August 27, 2008	EX-10.1	[Form of Note] August , 2008 QuantRx Biomedical Corporation 100 S. Main Street, Suite 300 Doylestown, PA 18901 RE: Bridge Loan Letter Agreement Ladies and Gentlemen: 1. Loan. This letter when fully executed will constitute a loan agreement (this ?Agreement?) between (the ?Lender?) and QuantRx Biomedical Corporation, a Nevada corporation (the ?Borrower?), pursuant to which the Lender, on the terms and conditions
August 27, 2008	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 21, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
August 27, 2008	EX-4.2	Form of Warrant to Purchase Shares of Common Stock of QuantRx, dated August 2008, issued by QuantRx in favor of lender. (incorporated by reference to Exhibit 4.2 filed with Form 8-K on August 27, 2008). THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
August 22, 2008	424B3	PROSPECTUS SUPPLEMENT NO. 11 Prospectus Supplement No. 11 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 11 Prospectus Supplement No. 11 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
August 20, 2008	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
August 15, 2008	424B3	PROSPECTUS SUPPLEMENT NO. 10 Prospectus Supplement No. 10 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 10 Prospectus Supplement No. 10 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Suppl
August 14, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION
August 8, 2008	424B3	PROSPECTUS SUPPLEMENT NO. 9 Prospectus Supplement No. 9 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October 2 Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 9 Prospectus Supplement No. 9 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Supplem
July 28, 2008	EX-4.2	Form of Warrant to Purchase Shares of Common Stock of QuantRx, dated June 2008, issued by QuantRx in favor of lender (incorporated by reference to Exhibit 4.2 filed with Form 8-K on July 28, 2008). THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
July 28, 2008	EX-4.1	QuantRx Biomedical Corporation Senior Secured Promissory Bridge Note THIS BRIDGE NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
July 28, 2008	EX-10.1	Very truly yours, By: Name: Walter W. Witoshkin Title: Chairman & CEO QuantRx Biomedical Corporation June , 2008 QuantRx Biomedical Corporation 100 S. Main Street, Suite 300 Doylestown, PA 18901 RE: Bridge Loan Letter Agreement Ladies and Gentlemen: 1. Loan. This letter when fully executed will constitute a loan agreement (this “Agreement”) between (the “Lender”) and QuantRx Biomedical Corporation, a Nevada corporation (the “Borrower”), pursuant to which the Lender, on the terms and conditions pr
July 28, 2008	EX-10.2	STOCK PLEDGE AGREEMENT STOCK PLEDGE AGREEMENT Stock Pledge Agreement (this “Agreement”), dated as of June , 2008, by and between QUANTRX BIOMEDICAL CORPORATION, a Nevada corporation, with its principal place of business at 100 South Main Street, Suite 300, Doylestown, Pennsylvania 18901 (the “Pledgor”) and (the “Secured Party”).
July 28, 2008	EX-10.3	PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT THIS PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT (this “Agreement”) is entered into as of this th day of June, 2008, by and between QUANTRX BIOMEDICAL CORPORATION, a Nevada corporation (the “Pledgor”), with its principal address at 100 S.
July 28, 2008	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 21, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
May 21, 2008	424B3	PROSPECTUS SUPPLEMENT NO. 8 Prospectus Supplement No. 8 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October 2 Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 8 Prospectus Supplement No. 8 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Supplem
May 15, 2008	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2008 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION
April 4, 2008	424B3	PROSPECTUS SUPPLEMENT NO. 7 Prospectus Supplement No. 7 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October 2 Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 7 Prospectus Supplement No. 7 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Supplem
March 31, 2008	10KSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-KSB x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-17119 QUANTRX BIOMEDICAL CORPORATION (
March 31, 2008	EX-21.1	Subsidiaries of QuantRx Biomedical Corporation As of December 31, 2007 EX-21.1 LIST OF SUBSIDIARIES Subsidiaries of QuantRx Biomedical Corporation As of December 31, 2007 Organized Under Laws of: Percentage of Voting Power FluoroPharma, Inc. Delaware 57.78 %
March 5, 2008	424B3	PROSPECTUS SUPPLEMENT NO. 6 Prospectus Supplement No. 6 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October 2 Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 6 Prospectus Supplement No. 6 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 and Prospectus Supplem
February 29, 2008	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 25, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
January 30, 2008	424B3	PROSPECTUS SUPPLEMENT NO. 5 Prospectus Supplement No. 5 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October 2 Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 5 Prospectus Supplement No. 5 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 and Prospectus Supplement No. 4 dated November 19, 2007 QUANTRX BIOMEDICAL COR
January 29, 2008	EX-10.1	[Form of Note] January 23, 2008 QuantRx Biomedical Corporation 100 S. Main Street, Suite 300 Doylestown, PA 18901 RE: Letter Loan Agreement Ladies and Gentlemen: 1. Loan. This letter when fully executed will constitute a loan agreement (this “Agreement”) between Platinum Long Term Growth VII LLC (the “Lender”) and QuantRx Biomedical Corporation, a Nevada corporation (the “Borrower”), pursuant to which the Lender
January 29, 2008	EX-4.1	QUANTRX BIOMEDICAL CORPORATION Senior Secured Convertible Promissory Note THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
January 29, 2008	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2008 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
January 29, 2008	EX-10.3	STOCK PLEDGE AGREEMENT STOCK PLEDGE AGREEMENT Stock Pledge Agreement (this “Agreement”), dated as of January 23, 2008, by and between QUANTRX BIOMEDICAL CORPORATION, a Nevada corporation, with its principal place of business at 100 South Main Street, Suite 300, Doylestown, Pennsylvania 18901 (the “Pledgor”) and PLATINUM LONG TERM GROWTH VII LLC, with a business address of 152 West 57th Street, 54th Floor, New York, New York 10019 (the “Secured Party”).
January 29, 2008	EX-10.2	PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT THIS PATENT, TRADEMARK AND COPYRIGHT SECURITY AGREEMENT (this “Agreement”) is entered into as of this 23rd day of January, 2008, by and between QUANTRX BIOMEDICAL CORPORATION, a Nevada corporation (the “Pledgor”), with its principal address at 100 S.
January 29, 2008	EX-4.2	Form of Warrant to Purchase Shares of Common Stock of QuantRx issued by QuantRx in favor of Investors (incorporated by reference to Exhibit 4.2 filed with Form 8-K on January 29, 2008). THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
December 31, 2007	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 20, 2007 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada 0-17119 33-0202574 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.
November 29, 2007	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 2)* QuantRx Biome sc13gza Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No.
November 19, 2007	424B3	PROSPECTUS SUPPLEMENT NO. 4 Prospectus Supplement No. 4 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 Prospectus Supplement No. 3 dated October 2 Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 4 Prospectus Supplement No. 4 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 and Prospectus Supplement No. 3 dated October 25, 2007 QUANTRX BIOMEDICAL CORPORATION This Prospectus Supplement No. 4 supplements ou
November 13, 2007	10QSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 o TRANSITION REPORT PURSUANT TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORAT
October 25, 2007	424B3	PROSPECTUS SUPPLEMENT NO. 3 Prospectus Supplement No. 3 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 Prospectus Supplement No. 2 dated August 20, 2007 QUANTRX BIOMEDICAL CORPORATION Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 3 Prospectus Supplement No. 3 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 and Prospectus Supplement No. 2 dated August 20, 2007 QUANTRX BIOMEDICAL CORPORATION This Prospectus Supplement No. 3 supplements our prospectus dated June 22, 2007, as supplemented by Pr
October 24, 2007	EX-4.1	QUANTRX BIOMEDICAL CORPORATION Senior Secured Convertible Promissory Note THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
October 24, 2007	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 16, 2007 QuantRx Biomedical Corporation (Exact name of Registrant as Specified in Charter) Nevada (State or Other Jurisdiction of Incorporation) 0-17119 (Commission File Number) 33-0202574 (IRS Employer Identification No.
October 24, 2007	EX-10.2	Form of Warrant to Purchase Shares of Common Stock of QuantRx Biomedical Corporation, dated October 2007 (incorporated by reference to Exhibit 10.2 filed with Form 8-K on October 24, 2007). THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?) OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR QUANTRX BIOMEDICAL CORPORATION SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.
October 24, 2007	EX-10.1	Very truly yours, LENDER: By: Name: Title: QuantRx Biomedical Corporation By: Name: Walter W. Witoshkin Title: Chairman & CEO [Form of Note] [Form of Warrant] October , 2007 QuantRx Biomedical Corporation 100 S. Main Street, Suite 300 Doylestown, PA 18901 RE: Letter Loan Agreement Ladies and Gentlemen: 1. Loan. This letter when fully executed will constitute a loan agreement (this “Agreement”) between (the “Lender”) and QuantRx Biomedical Corporation, a Nevada corporation (the “Borrower”), pursuant to which the Lender, on the terms and conditions provid
August 20, 2007	424B3	PROSPECTUS SUPPLEMENT NO. 2 Prospectus Supplement No. 2 to Prospectus dated June 22, 2007 as supplemented by Prospectus Supplement No. 1 dated July 13, 2007 QUANTRX BIOMEDICAL CORPORATION Table of Contents Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO.
August 14, 2007	10QSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2007 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL
July 13, 2007	424B3	PROSPECTUS SUPPLEMENT NO. 1 Prospectus Supplement No. 1 to Prospectus dated June 22, 2007 QUANTRX BIOMEDICAL CORPORATION Filed Pursuant to Rule 424(b)(3) File Number 333-142130 PROSPECTUS SUPPLEMENT NO. 1 Prospectus Supplement No. 1 to Prospectus dated June 22, 2007 QUANTRX BIOMEDICAL CORPORATION This Prospectus Supplement No. 1 supplements our prospectus dated June 22, 2007. The shares of our common stock that are the subject of the prospectus have been registered to permit their resale to the public by the selling
July 6, 2007	EX-99.1	EX-99.1 FLUOROPHARMA, INC. (a development stage company) AUDITED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2006 AND 2005 AND FOR THE YEARS THEN ENDED AND FOR THE PERIOD JUNE 13, 2003 (INCEPTION) THROUGH DECEMBER 31, 2006 (UNAUDITED) TABLE OF CONTENTS PAGE - INDEPENDENT AUDITOR'S REPORT ............................................ 2 FINANCIAL STATEMENTS Balance Sheets ........................................
July 6, 2007	EX-99.3	EX-99.3 QUANTRX BIOMEDICAL CORPORATION Pro Forma Condensed Combined Financial Statements March 31, 2007 (unaudited) QuantRx Biomedical Corporation Pro Forma Condensed Combined Financial Statements Index to Pro Forma Condensed Combined Financial Statements Introduction to Unaudited Pro Forma Condensed Combined Financial Statements 1 Unaudited Pro Forma Condensed Combined Balance Sheet 2 Unaudited Pro Forma
July 6, 2007	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 19, 2007 QuantRx Biomedic UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 19, 2007 QuantRx Biomedical Corporation (Exact Name of Registrant as Specified in Charter) Nevada (State or Other Jurisdiction of Incorporation) 0-17119 (Commission File Numbe
July 6, 2007	EX-99.2	EX-99.2 FLUOROPHARMA, INC. (a development stage company) REVIEWED FINANCIAL STATEMENTS AS OF MARCH 31, 2007 AND FOR THE THREE MONTHS ENDED MARCH 31, 2007 AND 2006 AND FOR THE PERIOD JUNE 13, 2003 (INCEPTION) THROUGH MARCH 31, 2007 (UNAUDITED) TABLE OF CONTENTS PAGE - ACCOUNTANTS' REVIEW REPORT .............................................. 2 FINANCIAL STATEMENTS Balance Sheets ............................
June 25, 2007	SB-2/A	As filed with the U.S. Securities and Exchange Commission on June 22, 2007 Table of Contents As filed with the U.S. Securities and Exchange Commission on June 22, 2007 Registration No. 333-142130 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 to FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QuantRx Biomedical Corporation (Name of small business issuer in its charter) Nevada 3841 330202574 (State o
May 15, 2007	10QSB	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-QSB x QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2007 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 0-17119 QUANTRX BIOMEDICAL CORPORATION
April 16, 2007	SB-2	As filed with the U.S. Securities and Exchange Commission on April 13, 2007 Table of Contents As filed with the U.S. Securities and Exchange Commission on April 13, 2007 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SB-2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QuantRx Biomedical Corporation (Name of small business issuer in its charter) Nevada 3841 330202574 (State or jurisdiction of incorporation or org
March 29, 2007	EX-7.19	EXHIBIT 7.19 exv7w19 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made this 6th day of February, 2007, between Robert & Lisa Allegra (“Buyer”), and Mark Capital, LLC (“Seller”).
March 29, 2007	EX-7.18	EXHIBIT 7.18 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this ?Agreement?) is made this 6th day of February, 2007, between Sydney F.
March 29, 2007	EX-7.20	EXHIBIT 7.20 exv7w20 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made this 6th day of February, 2007, between Rick van den Toorn (“Buyer”), and Mark Capital, LLC (“Seller”).
March 29, 2007	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities E Quantrx BioMedical Corporation Table of Contents OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response.

QTXB / QuantRx Biomedical Corporation - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Grundläggande statistik

SEC Filings

SEC Filings (Chronological Order)